BioSpace News Archive

According to the Centers for Disease Control and Prevention, more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.

It’s estimated there are more than 17,000 new cases of spinal cord injuries each year, which can cause permanent damage in patients.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2021.

- Published in the New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.*,¹

Centene Corporation (NYSE: CNC) announced today that Katie Casso has been named Senior Vice President, Corporate Controller, effective April 1 , 2021. Christopher Isaak , Senior Vice President, Corporate Controller and Chief Accounting Officer announced his retirement, effective April 30, 2021 .

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights on Thursday, March 18, 2021 .

- Significant progress achieved across pipeline of Bicycle ® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™) - Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones - First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share (the “Shares”), to funds managed by Deerfield Management Company, L.P.

Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021 − Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials Expected in the Second Half of 2021 − Projected Cash Runway Through 2023, Including Potential New Drug Application Submissions for Dry Eye Disease and Allergic Conjunctivitis

Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 23rd @ 1:00PM ET